Company intelligence

Omios Biologics

Hacking virus evolution to engineer tomorrow's cures.

Biotechnology Research
Stony Brook, US
2–10 employees
Founded 2023
2 public signals

About Omios Biologics

Nature spent millennia engineering viruses to manipulate human biology. We decoded it. Omios Biologics is a biotech company revolutionizing precision drug discovery through the Omios Discovery Engine (ODE), our computational platform that decodes viral-host interactions to build high-potency, high-selectivity therapeutics. By analyzing how over 270 human viruses exploit cellular pathways, ODE eliminates the guesswork of traditional drug discovery, pinpointing validated targets before a molecule is ever synthesized. Originally focused on developing biomarker-driven oncolytic viruses for hard-to-treat solid tumors (including breast, lung, pancreatic, and kidney cancers), Omios is now leveraging its platform across immunology, inflammation, metabolic, and neurodegenerative diseases. Powered by a team with deep expertise in virology, computational biology, and clinical drug development, Omios is replacing trial-and-error with predictive engineering to deliver the next generation of targeted cures.

Verified activity

Signals from Omios Biologics

2 published signals

Find the companies already in motion.

Customize signals around your market, buyers, competitors, and investment thesis.

© 2026 SeedOpsCompany intelligence.

SeedOps.